Medtronic PLC banner

Medtronic PLC
LSE:0Y6X

Watchlist Manager
Medtronic PLC Logo
Medtronic PLC
LSE:0Y6X
Watchlist
Price: 79.2553 USD -2.46% Market Closed
Market Cap: $106.4B

Wall St Price Targets

0Y6X Price Targets Summary
Medtronic PLC

Wall Street analysts forecast 0Y6X stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0Y6X is 100.5712 USD with a low forecast of 79.3349 USD and a high forecast of 127.9448 USD.

Lowest Forecast
Price Target
79.3349 USD
0% Upside
Average Forecast
Price Target
100.5712 USD
27% Upside
Highest Forecast
Price Target
127.9448 USD
61% Upside
Medtronic PLC Competitors:
Price Targets
GWH
ESS Tech Inc
107% Upside
NESR
National Energy Services Reunited Corp
10% Upside
FDMT
4D Molecular Therapeutics Inc
123% Upside

Revenue
Forecast

6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
6% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 4 years is 6%.

Gross Profit
Forecast

5% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
5% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 5%. The projected CAGR for the next 4 years is 6%.

Operating Income
Forecast

3% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-25%
Average Miss
3% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-25%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 4 years is 14%.

Pre-Tax Income
Forecast

2% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-37%
Average Miss
2% / Year
Past Growth
22% / Year
Estimated Growth
Estimates Accuracy
-37%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 2%. The projected CAGR for the next 3 years is 22%.

Net Income
Forecast

2% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-36%
Average Miss
2% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-36%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 4 years is 18%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0Y6X's stock price target?
Price Target
100.5712 USD

According to Wall Street analysts, the average 1-year price target for 0Y6X is 100.5712 USD with a low forecast of 79.3349 USD and a high forecast of 127.9448 USD.

What is the Revenue forecast for Medtronic PLC?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 4 years is 6%.

What is the Gross Profit forecast for Medtronic PLC?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 5%. The projected CAGR for the next 4 years is 6%.

What is the Operating Income forecast for Medtronic PLC?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 4 years is 14%.

What is the Pre-Tax Income forecast for Medtronic PLC?
Projected CAGR
22%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 2%. The projected CAGR for the next 3 years is 22%.

What is the Net Income forecast for Medtronic PLC?
Projected CAGR
18%

Over the last 13 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 4 years is 18%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett